US/UK/Canada

Share

Contacts

  • Mark Waugh

    CEO


    +1 (260) 804-1342

    • Links

    Pick a time period -
    Tags ( Active)

    OssDsign provides pre-release update on Q1 2026 performance

    OssDsign AB (publ.) today announces that preliminary revenue for the period January – March, 2026 will be USD 4.035 million or SEK 36.880 million.  The company attributes these results to a lack of sales channel expansion in late 2025, departure of certain sales personnel, and temporary slowdowns in key accounts due to contract negotiations.According to preliminary data, sales of OssDsign Catalyst from January to March 2026 were USD 4.035 million, representing a decline of 3.6%, or SEK 36.880 million, representing a decline of 17.1%, compared to the same quarter in the previous year. The

    New scientific paper shows OssDsign Cranial PSI results with zero implant-related complications and positive treatment outcomes in largest US case series to date

    Uppsala, Sweden, September 26, 2022. OssDsign AB (publ.) today announces that an independent clinical research team in New York, U.S., lead by Ralph Rahme, M.D., F.A.C.S., has published their clinical findings, describing treatment outcomes with OssDsign PSI in the largest U.S. cohort to date. The study included 18 patients who underwent cranioplasty, showing that the procedure was successful in all cases, and that no implant-related complications occurred during a 6-month median follow-up period. The clinical paper is published in the journal World Neurosurgery.OssDsign Cranial PSI is a

    OssDsign launches Cranial PSI in Japan and records first sales

    Uppsala, June 21, 2022. OssDsign AB (publ.) today announces that the company has completed its first sales of OssDsign Cranial PSI in Japan. The launch marks an important strategic milestone, following a period of postponed commercial activities due to the Covid-19 pandemic.OssDsign Cranial PSI is a patient-specific cranial implant made from 3D printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the unique calcium phosphate composition provides healing and

    New scientific paper further confirms osteointegration of OssDsign Cranial PSI implants

    OssDsign AB (publ) (“OssDsign” or the “Company”) today announced that independent researchers from Uppsala University Hospital, Sweden, have published a scientific paper in Journal of Neurosurgery describing bone integration in patients implanted with OssDsign Cranial PSI. Samples from four studied patients consistently show vascularized bone, integrating the OssDsign implant with surrounding native bone. This reaffirms the positive findings presented in previously published papers and further strengthens the benefits of OssDsign’s custom-made calcium phosphate implants.Patients undergoing

    OssDsign to present Sirakoss acquisition via live Webcast

    OssDsign AB (publ) will be hosting a live webcast where CEO Morten Henneveld will present the previously communicated acquisition of Sirakoss Ltd.  The webcast, which will run from 10:00 CET today November 4th, can be followed via the link: https://www.finwire.tv/webcast/ossdsign/presentation/ For further information, please contact: Morten Henneveld, VD, OssDsign AB Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com Certified Adviser:Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden,

    OssDsign announces intention to carry out a directed share issue as part of the financing of the acquisition of Sirakoss

    OssDsign AB (publ) (”OssDsign” or the ”Company”) hereby announces its intention to carry out a directed share issue of approximately SEK 55 million to Swedish and international investors (the “Directed Issue”). The Directed Issue is carried out as part of the financing of the acquisition of Sirakoss, a company specialized in bone graft substitute (the “Acquisition”), as announced by the Company earlier today. OssDsign has appointed ABG Sundal Collier to act as sole global coordinator and joint bookrunner and Erik Penser Bank to act as joint bookrunner in connection with the Directed Issue.

    OssDsign – strong sales in third quarter 2020

    OssDsign AB (publ) (“OssDsign”) publishes prelimary results for the third quarter 2020 ahead of plan in connection to the announcement of OssDsign’s acquisition of Sirakoss and the intention to carry out a directed share issue. OssDsign recorded strong sales growth in major territories. Total sales in the third quarter amounted to TSEK 6 481, an increase of 39% compared to the same period last year and the profit for the period amounted to TSEK -18 740.As communicated in separate press releases, OssDsign has signed an agreement to acquire the Scottish company Sirakoss and intends to carry

    OssDsign acquires Sirakoss, enters USD 4 billion bone graft market

    OssDsign AB (publ) (“OssDsign”), a leading bone-regeneration company with headquarters in Uppsala, Sweden, today announces the signing of an agreement to acquire the privately held, Scottish bone graft specialist company Sirakoss Ltd (“Sirakoss”). The acquisition broadens OssDsign’s product portfolio with the 510(k) cleared Osteo[3] ZP Putty, a next-generation synthetic bone graft substitute for use in orthopaedic surgery. OssDsign acquires all outstanding Sirakoss shares in an all-cash transaction, which is subject to customary closing conditions. The purchase price of USD 11 million, not

    New publication in high-impact scientific journal PNAS confirms the bone regenerative potential of OssDsign’s technology.

    A scientific article titled “In situ bone regeneration of large cranial defects using synthetic ceramic implants with a tailored composition and design” was recently published in the scientific journal PNAS (Proceedings of the National Academy of Sciences of the United States of America). The research article describes how OssDsign’s unique implant concept and proprietary material composition promote bone regeneration and osseointegration.OssDsign AB (publ) (“OssDsign”) today announced that a scientific article with the title “In situ bone regeneration of large cranial defects using

    OssDsign reports successful outcome at 6-month follow-up of clinical study on sinus augmentation

    OssDsign AB (publ) today announced positive interim results from a clinical study titled: “Safety and performance of granular calcium phosphate in augmentation of the maxillary sinus floor”. This study represents the first use of OssDsign’s proprietary calcium phosphate material in the oral cavity.As previously communicated, OssDsign has been sponsoring a clinical investigation of the safety and performance of the company’s proprietary calcium phosphate material to support bone growth in augmentation of the maxillary sinus floor. This open evaluation study is being performed on 20

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media